Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$51.71
-$1.19(-6.66%)
At close: 4:00 PM EST
$51.71
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$29.95 - $118.84
Previous CloseN/A
Volume371.20K
Average Volume (3M)772.96K
Market Cap
$3.25B
Enterprise Value$2.53B
Total Cash (Recent Filing)$823.11M
Total Debt (Recent Filing)$51.03M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Aug 18, 2026EPS Estimate
-2.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding42,916,590
10 Day Avg. Volume569,148
30 Day Avg. Volume772,962
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue16.23
Enterprise Value/Gross Profit-109.64
Enterprise Value/Ebitda-7.50
Forecast
1Y Price Target
$65.57Price Target Upside26.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-10.35
Revenue Forecast (FY)$179.56M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Balance Sheet StrengthVery low debt burdens give the company durable financial flexibility while it scales commercialization and funds trials. With minimal leverage, GRAIL can prioritize operating investment or evidence-generation without imminent refinancing risk, which supports strategic optionality over the next 2–6 months.
Material Cash Runway & Improving EBITDAA multi-hundred-million dollar cash balance plus year-over-year adjusted EBITDA improvement provides a runway to execute commercialization, evidence readouts and regulatory interactions. That liquidity cushions execution risk and allows continued investment in sales, studies and integrations.
Regulatory Progress And Large Evidence BasePMA acceptance and inclusion of large trials (PATHFINDER 2, NHS‑Galleri) strengthen long-term credibility with regulators and payers. A broad evidence base reduces clinical uncertainty and, if validated at ASCO readouts, can materially improve adoption and coverage prospects over coming quarters.
Bears Say
Sustained Cash BurnMeaningful negative operating and free cash flow implies ongoing dilution or strategic tradeoffs if revenue and margin improvements slip. Continued burn erodes runway over time and constrains optionality for commercial expansion unless improvements in unit economics persist.
Negative Core ProfitabilityA negative gross margin indicates the core test economics remain unprofitable at current pricing and scale. Persistent negative gross profit undermines path to sustainable operating profitability and means scaling volume alone may not convert to profits without price or cost structural changes.
Clinical Readout Setback And Perception RiskA non‑statistically significant primary endpoint in a major trial creates lasting questions around clinical utility and can slow provider, payer and employer adoption. The result increases the need for deeper data presentations and may delay coverage, complicating commercialization over multiple quarters.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $29.95 and its highest was $118.84 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $3.25B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on May 05, 2026. The company reported -$2.29 earnings per share for the quarter, beating the consensus estimate of -$2.763 by $0.473.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -2.65.
How many shares outstanding does Grail Inc have?
Grail Inc has 42,916,590 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$2.29 in its last earnings report, beating expectations of -$2.763. Following the earnings report the stock price went up 15.349%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.57 (26.81% Upside)
$65.57 (26.81% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
79.89%
12-Months-Change
Fundamentals
Return on Equity
-16.42%
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical and regulatory progress: test volumes grew 50% YoY, screening revenue rose 37% YoY, adjusted gross profit improved 38% YoY, PMA was accepted, and large trial datasets and upcoming ASCO readouts support the evidence base. At the same time, the NHS-Galleri primary combined endpoint was not met, ASP pressure and continued operating losses persist, media scrutiny and competitive activity create near-term headwinds, and regulatory/timing uncertainties (including possible FDA AdCom and CMS coverage) remain. Overall, positives around volume growth, margins improvement, cash runway, partnerships and regulatory progress outweigh the challenges, but the company still faces execution and perception risks that will need to be addressed in coming quarters.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$65.57
▲(26.81% Upside)
Technical Analysis
Ownership Overview
11.70% Insiders
12.49% Mutual Funds
0.45% Other Institutional Investors
60.02% Public Companies and Individual Investors